IL114809A0 - Mutant br96 antibodies - Google Patents

Mutant br96 antibodies

Info

Publication number
IL114809A0
IL114809A0 IL11480995A IL11480995A IL114809A0 IL 114809 A0 IL114809 A0 IL 114809A0 IL 11480995 A IL11480995 A IL 11480995A IL 11480995 A IL11480995 A IL 11480995A IL 114809 A0 IL114809 A0 IL 114809A0
Authority
IL
Israel
Prior art keywords
mutant
antibodies
variable region
math
polypeptides
Prior art date
Application number
IL11480995A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Ixsys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/285,936 external-priority patent/US5728821A/en
Application filed by Bristol Myers Squibb Co, Ixsys Inc filed Critical Bristol Myers Squibb Co
Publication of IL114809A0 publication Critical patent/IL114809A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL11480995A 1994-08-04 1995-08-02 Mutant br96 antibodies IL114809A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/285,936 US5728821A (en) 1994-08-04 1994-08-04 Mutant BR96 antibodies reactive with human carcinomas
US08/487,860 US5792456A (en) 1994-08-04 1995-06-07 Mutant BR96 antibodies reactive with human carcinomas

Publications (1)

Publication Number Publication Date
IL114809A0 true IL114809A0 (en) 1995-12-08

Family

ID=26963478

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11480995A IL114809A0 (en) 1994-08-04 1995-08-02 Mutant br96 antibodies

Country Status (9)

Country Link
US (1) US5792456A (ja)
EP (1) EP0699756B1 (ja)
JP (1) JPH08191692A (ja)
AT (1) ATE262038T1 (ja)
AU (1) AU2834995A (ja)
CA (1) CA2155397A1 (ja)
DE (1) DE69532701D1 (ja)
IL (1) IL114809A0 (ja)
MX (1) MX9503362A (ja)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6247995B1 (en) 1996-02-06 2001-06-19 Bruce Bryan Bioluminescent novelty items
US7247302B1 (en) * 1996-08-02 2007-07-24 Bristol-Myers Squibb Company Method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
DE69738522T2 (de) * 1996-08-02 2009-04-02 Bristol-Myers Squibb Co. Ein verfahren zur inhibierung immunglobulininduzierter toxizität aufgrund von der verwendung von immunoglobinen in therapie und in vivo diagnostik
US6416960B1 (en) 1996-08-08 2002-07-09 Prolume, Ltd. Detection and visualization of neoplastic tissues and other tissues
US6458547B1 (en) 1996-12-12 2002-10-01 Prolume, Ltd. Apparatus and method for detecting and identifying infectious agents
WO1999006834A2 (en) * 1997-08-04 1999-02-11 Ixsys, Incorporated Methods for identifying ligand specific binding molecules
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
DK1265928T3 (da) 2000-01-27 2010-11-15 Medimmune Llc RSV-neutraliserende antistoffer med ultra høj affinitet
AU2001240020B9 (en) 2000-03-01 2008-12-04 Medimmune, Llc High potency recombinant antibodies and method for producing them
US6599441B1 (en) * 2000-07-18 2003-07-29 Emerald Biostructures, Inc. Crystallization solutions
US7179900B2 (en) 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
EP1420803A1 (en) * 2001-08-08 2004-05-26 Board Of Regents, The University Of Texas System Method for amplifying expression from a cell specific promoter
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
AT413487B (de) * 2002-08-12 2006-03-15 Igeneon Krebs Immuntherapie Verwendung von antikörpern gegen ein tumor-assoziiertes antigen
JP4462964B2 (ja) * 2003-03-10 2010-05-12 第一三共株式会社 癌特異的抗原を標的とした抗体
TW200539855A (en) * 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
KR20080073293A (ko) * 2005-10-14 2008-08-08 메디뮨 엘엘씨 항체 라이브러리의 세포 디스플레이
US8377448B2 (en) * 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
US20080131431A1 (en) * 2006-05-15 2008-06-05 Viral Logic Systems Technology Corp. CD47 related compositions and methods for treating immunological diseases and disorders
US7858752B2 (en) * 2006-12-05 2010-12-28 Abbott Laboratories Recombinant antibodies against hepatitis C virus and methods of obtaining and using same
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
SG11201506088RA (en) 2013-03-11 2015-09-29 Genzyme Corp Hyperglycosylated binding polypeptides
HUE061339T2 (hu) 2014-03-19 2023-06-28 Genzyme Corp Targetáló csoportok helyspecifikus glikotechnikai átalakítása
EP3802604A1 (en) 2018-05-31 2021-04-14 Glyconex Inc. Therapeutic antibodies binding to biantennary lewis b and lewis y antigens

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4713352A (en) * 1981-08-31 1987-12-15 Sloan-Kettering Institute For Cancer Reseach Monoclonal antibody panel for early diagnosis and therapy of renal carcinoma
US4612282A (en) * 1981-12-15 1986-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Monoclonal antibodies reactive with human breast cancer
US4507391A (en) * 1982-04-02 1985-03-26 Sloan-Kettering Institute For Cancer Research Method for detecting the presence of GD3 ganglioside
US4713351A (en) * 1983-01-28 1987-12-15 The University Of Rochester Monoclonal antibody directed to an antigen derived from human ovarian tumors and a radioimmunoassay using the antibody
US4579827A (en) * 1983-03-11 1986-04-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
ZA858371B (en) * 1984-11-02 1987-03-25 Oncogen Monoclonal antibodies for human non-small cell lung carcinomas
US4708930A (en) * 1984-11-09 1987-11-24 Coulter Corporation Monoclonal antibody to a human carcinoma tumor associated antigen
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
PT89107A (pt) * 1987-11-30 1989-11-30 Idec Pharma Corp Metodo e meios para a seleccao de anticorpos anti-idiotipos e seu uso para o diagnostico, monitorizacao, tratamento e/ou prevencao de doencas cancerosas, da autoimunidade ou infecciosas
IL94872A (en) * 1989-06-30 1995-03-30 Oncogen Monoclonal or chimeric antibodies that react with human carcinoma, recombinant proteins that contain their anti-binding site, pharmaceutical preparations and kits that contain the
JPH06501705A (ja) * 1990-11-05 1994-02-24 ブリストル−マイアーズ　スクイブ　カンパニー 抗−腫瘍抗体及び生物学的活性剤の組合せによる相乗治療
CA2452130A1 (en) * 1992-03-05 1993-09-16 Francis J. Burrows Methods and compositions for targeting the vasculature of solid tumors

Also Published As

Publication number Publication date
EP0699756A1 (en) 1996-03-06
ATE262038T1 (de) 2004-04-15
CA2155397A1 (en) 1996-02-05
EP0699756B1 (en) 2004-03-17
MX9503362A (es) 1997-08-30
DE69532701D1 (de) 2004-04-22
AU2834995A (en) 1996-02-15
US5792456A (en) 1998-08-11
JPH08191692A (ja) 1996-07-30

Similar Documents

Publication Publication Date Title
IL114809A0 (en) Mutant br96 antibodies
GB9828628D0 (en) Novel ligand
NZ503850A (en) April - a novel protein with growth effects
HU9601448D0 (en) Novel apoptosis-modulating proteins, dna encoding the proteins and methods of use thereof
ZA957846B (en) Overexpression of mammalian and viral proteins
EP0769554A3 (en) Human CNP gene and precursor protein
MX9902661A (en) High level expression of proteins
HK1042098A1 (en) Interferon-beta fusion proteins and uses
EP0255011A3 (en) Human inter-alpha-trypsin inhibitor gene
EP0920501B8 (en) Neuritin, a neurogene
AU7001994A (en) Mutant polypeptide of protein kinase c, nucleic acid sequences coding for said polypeptide and use thereof
EP0665888A4 (en) ALLERGEN FROM RAYGRASS POLLEN.
GB9416536D0 (en) Orphan receptor
DE3582136D1 (de) Gen fuer ein protein mit insektizider wirkung.
EP0816504A3 (en) Platelet activating factor acetylhdrolase, and gene thereof
GB2216127B (en) Modified dna sequences coding for mutant endotoxins of bacillus thuringiensis
AU1178495A (en) Dna sequences encoding porcine pancreatic carboxypeptidase b
EP0490383A3 (en) Peptides of the hiv-gag protein, their preparation and use
WO2000029564A3 (en) Human glycine transporter type 2
WO1998027206A3 (fr) Polypeptides de la famille 'basic helix-loop-helix' bhlh, sequences d'acides nucleiques correspondantes
WO1990003394A3 (fr) Nouvelles lymphokines, sequences d'adn codant pour ces lymphokines et compositions pharmaceutiques contenant ces lymphokines
AU2379092A (en) Nucleotide sequences coding for ribosome inactivating proteins
MXPA01011563A (es) Una novedosa proteina 5 relacionada al factro-h y anticuerpos relacionados.
EP0754754A4 (en) PROTEIN GENE LINKED TO FK506
HUT65816A (en) A novel translational activating sequence